RxDoctor Payments Data

Jeannie Farris, APRN

Family Medicine · Panama City, FLNPI 1063031763

Payments from drug & device makers

$18,757in general payments, 2019–2025

Across 673 payments — averaging $27.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$6K
  • AbbVie$1K
  • Novartis$807
  • Pfizer$794
  • UCB, Inc.$729
  • Lilly USA, LLC$728
  • plus $8K from 51 others

What the payments were for

  • Travel & lodging$4,99527%
  • Food & beverage$13,75173%
  • Education$110%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$18,757 in reported general payments places this provider in the 95th percentile of 7,282 family medicine providers in Florida.

See all family medicine providers in Florida

Medicare billing

Part B allowed, 2024
$135,956
Medicare patients
545
Services billed
1,862

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VumerityDiroximel Fumarate11$95,836
Nurtec OdtRimegepant Sulfate43$80,838
UbrelvyUbrogepant37$51,696
NuplazidPimavanserin Tartrate11$45,327
RexultiBrexpiprazole21$43,431
Aimovig AutoinjectorErenumab-Aooe60$42,338
QuliptaAtogepant28$37,972
Emgality PenGalcanezumab-Gnlm35$35,762
XcopriCenobamate20$23,494
RytaryCarbidopa/Levodopa26$20,564
SavellaMilnacipran Hcl11$12,548
BelsomraSuvorexant26$11,502
Gabapentin500$9,795
Lacosamide52$8,576
Levetiracetam218$8,364

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieUbrelvy, Qulipta, Savella$1,412$102,21576 claims
BiogenVumerity$408$95,83611 claims
PfizerNurtec Odt$794$80,83843 claims
Acadia Pharmaceuticals IncNuplazid$438$45,32711 claims
Otsuka America Pharmaceutical, Inc.Rexulti$235$43,43121 claims
SK Life Science, Inc.Xcopri$501$23,49420 claims
Amneal Pharmaceuticals LLCRytary$81$20,56426 claims
MerckBelsomra$102$11,50226 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 7,282 family medicine providers in Florida.

Other family medicine in Panama City

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →